Inactive Instrument

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	288M 252M 234M 215M 406M 27.73B 411M 2.79B 1.09B 13.59B 1.08B 1.06B 46.93B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	384M 337M 312M 287M 541M 36.99B 548M 3.72B 1.46B 18.13B 1.44B 1.41B 62.59B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.6x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
26/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
23/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
26/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
14/08/25	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	31/05/2007
Linda Powers CEO	Chief Executive Officer	71	07/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	31/12/1999

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	31/12/1997
Linda Powers CHM	Chairman	71	16/05/2007
Navid Malik BRD	Director/Board Member	57	31/03/2012

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.80%	-0.83%	+52.79%	+86.50%	54.69B
ARGENX SE	+0.88%	-0.13%	+57.39%	+54.58%	53.79B
BIONTECH SE	+0.18%	+2.13%	-15.22%	-14.97%	23.31B
INSMED INCORPORATED	+1.50%	-1.35%	+5.68%	+415.28%	23.2B
WUXI BIOLOGICS (CAYMAN) INC.	+0.26%	-1.52%	+39.07%	-3.97%	20.03B
GENMAB A/S	+0.30%	-0.40%	+33.13%	-33.46%	17.31B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.68%	-4.01%	+36.24%	+545.36%	15.36B
PHARMAESSENTIA CORPORATION	0.00%	-2.08%	+165.40%	+297.92%	14.99B
EXELIXIS, INC.	+1.06%	+0.63%	+26.80%	+185.02%	13.96B
Average	+0.75%	-1.55%	+44.59%	+170.25%	26.29B
Weighted average by Cap.	+0.94%	-1.50%	+44.45%	+134.05%

	2026 *	2027 *
Net sales	-	38.93M 34.13M 31.62M 29.1M 54.88M 3.75B 55.54M 377M 148M 1.84B 146M 143M 6.34B
Net income	-	-
Net Debt	96.08M 84.21M 78.03M 71.82M 135M 9.25B 137M 931M 364M 4.53B 361M 353M 15.66B	125M 110M 101M 93.39M 176M 12.03B 178M 1.21B 474M 5.9B 469M 459M 20.36B

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile